Medicina
Saila
Dana–Farber Cancer Institute
Boston, Estados UnidosDana–Farber Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (18)
2024
-
Impact of individual level uncertainty of lung cancer polygenic risk score (PRS) on risk stratification
Genome Medicine, Vol. 16, Núm. 1
-
Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer
Cancer Epidemiology Biomarkers and Prevention, Vol. 33, Núm. 3, pp. 419-425
-
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 9, pp. 1889-1905
2023
-
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer
Cancer research, Vol. 83, Núm. 19, pp. 3284-3304
-
Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions
Journal of the National Cancer Institute, Vol. 115, Núm. 6, pp. 712-732
2022
-
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Cancer research, Vol. 82, Núm. 20, pp. 3673-3686
2021
-
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer
Genome Medicine, Vol. 13, Núm. 1
-
Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer
Genetic Epidemiology, Vol. 45, Núm. 1, pp. 99-114
-
The ESR1 Mutations: From Bedside to Bench to Bedside
Cancer Research
2019
-
Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)
Nature Communications
-
Shared heritability and functional enrichment across six solid cancers
Nature Communications, Vol. 10, Núm. 1
2018
-
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Leukemia, Vol. 32, Núm. 12, pp. 2546-2557
2017
-
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
BMC Cancer, Vol. 17, Núm. 1
-
Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents
Journal of Clinical Oncology, Vol. 35, Núm. 14, pp. 1591-1597
2015
-
Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types
Journal of the National Cancer Institute, Vol. 107, Núm. 12
-
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
British Journal of Cancer, Vol. 112, Núm. 7, pp. 1190-1198
-
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Blood, Vol. 126, Núm. 3, pp. 291-299
2014
-
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33
Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633